A clinical trial to study the effect and safety of Lobeglitazone Vs. Pioglitazone in Diabetic patients.

Assessment of Clinical Efficacy and Safety of Lobeglitazone Vs. Pioglitazone in T2DM Patients- A Prospective Open Label Randomized Controlled Trial. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/063774

Enrollment

Registered

2024-03-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases

Interventions

Intervention1: Lobeglitazone: Lobeglitazone is a Novel thiazolidinedione drug to treat Type 2 Diabetes Mellitus. The dose of 0.5 mg of Lobeglitazone will be administered orally once a day for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: Patient willing to give informed consent form. Patient with Body mass index 18.5 to 25

Exclusion criteria

Exclusion criteria: Patients with other complications like cardiac, renal, gastrointestinal, and hematological disorders. Patients has undergone major surgery. A patient who has known or suspected hypersensitivity to the study drugs. Patients with pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
Fasting Blood Glucose (FBG) Post Prandial Blood Glucose(PPBG) HbA1CTimepoint: 1 month Interval	—

Secondary

Measure	Time frame
Lipid ProfileTimepoint: 3 months interval	—

Countries

India

Contacts

Public ContactMr M Balamurugan

SRM Institute of Science and Technology

saruprabakar@gmail.com7010530419

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026